WO2021236997A3 - Potent neutralizing antibodies against sars-cov-2, generation and uses thereof - Google Patents

Potent neutralizing antibodies against sars-cov-2, generation and uses thereof Download PDF

Info

Publication number
WO2021236997A3
WO2021236997A3 PCT/US2021/033512 US2021033512W WO2021236997A3 WO 2021236997 A3 WO2021236997 A3 WO 2021236997A3 US 2021033512 W US2021033512 W US 2021033512W WO 2021236997 A3 WO2021236997 A3 WO 2021236997A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
generation
antibodies against
neutralizing antibodies
potent neutralizing
Prior art date
Application number
PCT/US2021/033512
Other languages
French (fr)
Other versions
WO2021236997A2 (en
Inventor
David D. Ho
Yaoxing Huang
Lihong Liu
Manoj S. Nair
Pengfei Wang
Jian Yu
Yang Luo
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112022023467A priority Critical patent/BR112022023467A2/en
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Priority to CA3184184A priority patent/CA3184184A1/en
Priority to IL298263A priority patent/IL298263A/en
Priority to CN202180059673.2A priority patent/CN116829177A/en
Priority to EP21807600.8A priority patent/EP4153625A4/en
Priority to AU2021277373A priority patent/AU2021277373A1/en
Priority to JP2022570668A priority patent/JP2023526469A/en
Priority to KR1020227044068A priority patent/KR20230024904A/en
Priority to MX2022014420A priority patent/MX2022014420A/en
Priority to US17/999,387 priority patent/US20230203134A1/en
Publication of WO2021236997A2 publication Critical patent/WO2021236997A2/en
Publication of WO2021236997A3 publication Critical patent/WO2021236997A3/en
Priority to CONC2022/0018192A priority patent/CO2022018192A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject matter described herein relates to potent monoclonal and bispecific antibodies capable of neutralizing a SARS-CoV-2 viruses and methods of generating the antibodies.
PCT/US2021/033512 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof WO2021236997A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2021277373A AU2021277373A1 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against SARS-CoV-2, generation and uses thereof
CA3184184A CA3184184A1 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
IL298263A IL298263A (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
CN202180059673.2A CN116829177A (en) 2020-05-20 2021-05-20 Effective neutralizing antibodies against SARS-CoV-2 and production and use thereof
EP21807600.8A EP4153625A4 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
BR112022023467A BR112022023467A2 (en) 2020-05-20 2021-05-20 POWERFUL NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2, THEIR GENERATION AND USES
JP2022570668A JP2023526469A (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against SARS-CoV-2, their generation and use
US17/999,387 US20230203134A1 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
MX2022014420A MX2022014420A (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof.
KR1020227044068A KR20230024904A (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against SARS-COV-2, their generation and uses
CONC2022/0018192A CO2022018192A2 (en) 2020-05-20 2022-12-15 Powerful neutralizing antibodies against sars-cov-2, generation and uses thereof

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US202063027935P 2020-05-20 2020-05-20
US63/027,935 2020-05-20
US202063032518P 2020-05-29 2020-05-29
US63/032,518 2020-05-29
US202063039977P 2020-06-16 2020-06-16
US63/039,977 2020-06-16
US202063060116P 2020-08-02 2020-08-02
US63/060,116 2020-08-02
US202063063106P 2020-08-07 2020-08-07
US63/063,106 2020-08-07
US202063117908P 2020-11-24 2020-11-24
US63/117,908 2020-11-24
US202063123767P 2020-12-10 2020-12-10
US63/123,767 2020-12-10
US202163165729P 2021-03-24 2021-03-24
US63/165,729 2021-03-24

Publications (2)

Publication Number Publication Date
WO2021236997A2 WO2021236997A2 (en) 2021-11-25
WO2021236997A3 true WO2021236997A3 (en) 2022-09-29

Family

ID=78707603

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2021/033513 WO2021236998A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
PCT/US2021/033510 WO2021236995A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
PCT/US2021/033511 WO2021236996A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
PCT/US2021/033512 WO2021236997A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/US2021/033513 WO2021236998A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
PCT/US2021/033510 WO2021236995A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
PCT/US2021/033511 WO2021236996A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Country Status (12)

Country Link
US (3) US20230203138A1 (en)
EP (1) EP4153625A4 (en)
JP (1) JP2023526469A (en)
KR (1) KR20230024904A (en)
AU (1) AU2021277373A1 (en)
BR (1) BR112022023467A2 (en)
CA (1) CA3184184A1 (en)
CL (1) CL2022003215A1 (en)
CO (1) CO2022018192A2 (en)
IL (1) IL298263A (en)
MX (1) MX2022014420A (en)
WO (4) WO2021236998A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230203138A1 (en) * 2020-05-20 2023-06-29 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
WO2024089277A2 (en) * 2022-10-27 2024-05-02 Oxford University Innovation Limited Antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287348B2 (en) * 2007-09-10 2019-05-14 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778283A2 (en) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccine compositions for treating coronavirus infection
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
CN101627055A (en) * 2006-09-05 2010-01-13 梅达雷克斯公司 The antibody of bone morphogenetic protein and acceptor thereof and their using method
WO2009128963A2 (en) * 2008-01-17 2009-10-22 Humab, Llc Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
CN108610416B (en) * 2008-10-13 2022-01-14 生物医学研究所 Dengue virus neutralizing antibodies and uses thereof
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US9587012B2 (en) * 2013-12-02 2017-03-07 Aaron Diamond Aids Research Center Bispecific HIV-1 neutralizing antibodies
WO2016138160A1 (en) * 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
JP2018524284A (en) * 2015-05-18 2018-08-30 ユーリカ セラピューティックス， インコーポレイテッド Anti-ROR1 antibody
US10358497B2 (en) * 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
CR20180365A (en) * 2015-12-16 2018-09-28 Amgen Inc PROTEINS OF UNION TO THE ANTI-TL1A / ANTI-TNF-a BISPECTIVE ANTIGEN AND ITS USES
TWI848953B (en) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 Multi-specific binding proteins for cancer treatment
PE20211604A1 (en) * 2018-07-09 2021-08-23 Five Prime Therapeutics Inc ILT4 UNION ANTIBODIES
US20230203138A1 (en) * 2020-05-20 2023-06-29 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287348B2 (en) * 2007-09-10 2019-05-14 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 13 November 2019 (2019-11-13), "Homo sapiens (Human) IG c373_heavy_lGHV1- 69_IGHD1-26_IGHJ6", XP055883889, Database accession no. AOA5C2GNE1_HUMAN *
LV ET AL.: "Cross-reactive antibody 1 response between SARS-CoV-2 and SARS-CoV infections", BIORXIV PREPRINT, 17 March 2020 (2020-03-17), pages 1 - 20, XP055800520, Retrieved from the Internet <URL:https://doi.org/10.1101/2020.03.15.993097> [retrieved on 20210702] *
PINTO ET AL.: "Structural and functional analysis of a potent sarbecovirus neutralizing antibody", BIORXIV PREPRINT, 9 April 2020 (2020-04-09), pages 1 - 28, XP055737085, Retrieved from the Internet <URL:https://www.biorxiv.org/contentlbiorxiv/early/2020/04/09/2020.04.07.023903.1.full.pdf> [retrieved on 20220526] *

Also Published As

Publication number Publication date
WO2021236995A2 (en) 2021-11-25
WO2021236997A2 (en) 2021-11-25
IL298263A (en) 2023-01-01
KR20230024904A (en) 2023-02-21
WO2021236998A2 (en) 2021-11-25
MX2022014420A (en) 2023-03-21
WO2021236996A2 (en) 2021-11-25
US20230203134A1 (en) 2023-06-29
WO2021236998A3 (en) 2021-12-16
BR112022023467A2 (en) 2023-03-28
CA3184184A1 (en) 2021-11-25
WO2021236996A3 (en) 2022-11-17
EP4153625A4 (en) 2024-09-25
AU2021277373A1 (en) 2023-01-05
JP2023526469A (en) 2023-06-21
US20240002476A1 (en) 2024-01-04
WO2021236998A9 (en) 2022-03-31
US20230203138A1 (en) 2023-06-29
EP4153625A2 (en) 2023-03-29
CO2022018192A2 (en) 2023-03-17
WO2021236995A3 (en) 2022-09-15
CL2022003215A1 (en) 2023-07-07

Similar Documents

Publication Publication Date Title
PH12020500177A1 (en) Bcma monoclonal antibody-drug conjugate
WO2021236997A3 (en) Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
EA201992469A1 (en) ANTIGEN SPECIFIC IMMUNE EFFECTIVE CELLS
PE20141722A1 (en) ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION
MX2022000893A (en) Method of obtaining mitochondria from cells and obtained mitochondria.
MX2020012589A (en) Monospecific and multispecific anti-tmeff2 antibodies and there uses.
MX2022014653A (en) Coronavirus antigen compositions and their uses.
WO2023044006A8 (en) Compositions and methods for producing circular polyribonucleotides
PH12019502475A1 (en) Transmitting method for synchronization signal, receiving method for synchronization signal, and related devices
MX2021014973A (en) High affinity anti-cd3 antibodies, and methods for their generation and use.
MX2023004054A (en) Anti-dectin-1 antibodies and methods of use thereof.
ZA202206643B (en) Mutant of inner membrane protein, and method for producing target product by using same
MX2022015403A (en) Activated carbon modified by atomic layer deposition and methods thereof.
MX2023005841A (en) Anti-marco antibodies and uses thereof.
CR20230581A (en) Anti-ccr8 antibodies and uses thereof
ZA202206670B (en) Anti-ly6g6d antibodies and methods of use
MX2022013135A (en) Humanized anti-complement factor bb antibodies and uses thereof.
MX2023014154A (en) Anti-ccr8 antibodies.
WO2018128457A3 (en) Method for performing channel-coding of information on basis of polar code
MX2022002269A (en) Transformed plants and methods for making and using the same.
AU2018325899A1 (en) Method for producing influenza HA split vaccine
ZA202303479B (en) Microorganism for producing putrescine and process for producing putrescine by using same
WO2023010065A3 (en) Compositions and methods for anti-pacap antibodies
WO2020161139A3 (en) Method of producing ions and apparatus
MX2022002563A (en) Novel promoter and method for producing desired substance using same.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21807600

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2022570668

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3184184

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022023467

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: NC2022/0018192

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021807600

Country of ref document: EP

Effective date: 20221220

ENP Entry into the national phase

Ref document number: 2021277373

Country of ref document: AU

Date of ref document: 20210520

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202180059673.2

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112022023467

Country of ref document: BR

Free format text: EXIGENCIA:1 - FAVOR EFETUAR, EM ATE 60 (SESSENTA) DIAS, O PAGAMENTO DE GRU CODIGO DE SERVICO 260 PARA A REGULARIZACAO DO PEDIDO, CONFORME ART 2O 1O DA RESOLUCAO 189/2017 E NOTA DE ESCLARECIMENTO PUBLICADA NA RPI 2421 DE 30/05/2017, UMA VEZ QUE A PETICAO NO 870230001673 DE 06/01/2023 APRESENTA DOCUMENTOS REFERENTES A 2 SERVICOS DIVERSOS (TRADUCAO DOS DOCUMENTOS APRESENTADOS NO DEPOSITO E MODIFICACAO NO TITULO DO PEDIDO) TENDO SIDO PAGA SOMENTE 1 RETRIBUICAO. DEVERA SER PAGA MAIS 1 (UMA) GRU CODIGO DE SERVICO 260 E A GRU CODIGO DE SERVICO 207 REFERENTE A RESPOSTA DESTA EXIGENCIA. 2 ? APRESENTE NOVA VIA DE DESENHOS, UMA VEZ QUE NO CONTEUDO APRESENTADO NA PETICAO 870230001673 DE 06/01/2023 A PA

ENP Entry into the national phase

Ref document number: 112022023467

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221118